title: Do GLP-1-based therapies increase cancer risk?
authors.affiliation: Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Harz, Germany. michael.nauck@diabeteszentrum.de
authors.forename: Michael A
authors.initials: MA
authors.lastname: Nauck
authors.forename: Nele
authors.initials: N
authors.lastname: Friedrich
mesh_terms: D000818:Animals; D004359:Drug Therapy, Combination; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000209:etiology; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D010190:Pancreatic Neoplasms / Q000453:epidemiology*; D010195:Pancreatitis / Q000453:epidemiology / Q000209:etiology; D012307:Risk Factors; D013964:Thyroid Neoplasms / Q000453:epidemiology*
chemical_list: D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1